Antithrombin Market Size, Share and Industry Analysis By Application (Therapeutics, Research, Diagnostics & Others), Source (Human, Goat Milk), Dosage Form (Lyophilized, Liquid) & Regional Forecast, 2020 - 2029 (Includes COVID-19 Business Impact)

                                          
We have updated Antithrombin Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Antithrombin market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Antithrombin market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Antithrombin Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Antithrombin Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Antithrombin Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
LFB USA
  
Grifols
  
Shire Plc.
  
CSL Limited
  
Kedrion S.p.A.
  
Octapharma AG
  
Lee Biosolutions
  
Scripps Laboratories Inc.
  
Other prominent players

Report Overview

Growing adoption of antithrombin combined with heparin is expected to positively impact the growth of the market. Existing new product development and ongoing clinical trials to discover novel applications of antithrombin, cumulatively considered to support the growth of market during the forecast period.

The report provides qualitative and quantitative insights of antithrombin industry and detailed analysis of market size & growth rate for all possible segments in the market. The market is segmented on the basis of, source type, and dosage form. On the basis of application type, the antithrombin market is categorized into therapeutics, research, and diagnostics & others.

Based on source, the antithrombin market is segmented into human, goat milk (recombinant), and others. Based on dosage form, the market is segmented into lyophilized form and liquid form. Geographically, the market is segmented into four major regions, namely North America, Europe, Asia Pacific, and the Rest of the World. The regions are further categorized into countries.

Along with this, the report provides an elaborative analysis of market dynamics and competitive landscape. Various key insights provided in the report are key brand analysis, key industry developments - mergers, acquisitions and partnerships, reimbursement scenario, and key performance indicators for the global antithrombin market

SEGMENTATION

By Application

  
      Therapeutics
  
      Research
  
      Diagnostics & Others

By Source

  
      Human
  
      Goat Milk (Recombinant)
  
      Others

By Dosage Form

  
      Lyophilized
  
      Liquid

By Geography

  
      North America (USA and Canada)
  
      Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)
  
      Asia Pacific (Japan, China, Australia & New Zealand, and Rest of Asia Pacific)
  
      Rest of the World

Key Industry Developments

In Feb 2009, The Food and Drug Administration (FDA) has approved an Rx called ATryn, which is made from goats genetically altered to produce the blood-thinning protein antithrombin.

In Jan 2013, GTC Biotherapeutics, Inc., an LFB Group Company, announced name change to revo biologics and renewed commitment to Evolving Recombinant Medicine.